The N-MOmentum pivotal trial (NCT02200770) is the largest phase 3 clinical trial in NMOSD and the only phase 3 trial that collected MRI data, which was incorporated into its attack adjudication ...

Roche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis optica spectrum disorder (NMOSD), setting up regulatory filings. The interleukin-6-targeting ...

NMOSD Patients At Greater Risk of Type 2 Diabetes A recent analysis found an elevated risk of type 2 diabetes among patients with neuromyelitis optica spectrum disorder, with steroid use possibly ...

Most of these quiz questions are derived from recent literature and guideline updates. Are you up to date? Compare your score with those of your physician colleagues. We provide links to the ...

A swift and accurate diagnosis is crucial when treating any disease, but especially a rare one. Sadly, people with particularly rare diseases that present like more recognisable conditions face a ...